Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0005944
Disease: Metabolic Bone Disorder
Metabolic Bone Disorder 		0.010 Biomarker group BEFREE Collectively, our present study unveiled a novel role for PCK2 in integrating autophagy and bone formation, providing a potential target for stem cell-based bone tissue engineering that may lead to improved therapies for metabolic bone diseases.Stem Cells 2019;37:1542-1555. 31574189 2019
CUI: C0025517
Disease: Metabolic Diseases
Metabolic Diseases 		0.010 Biomarker group BEFREE The decompensation of PCK2 leads to various energy metabolic disorders. 31574189 2019
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.010 Biomarker phenotype BEFREE Accordingly, PQBP1 and PCK2 are crucial for recurrence and metastasis in OS, and these findings provide a molecular basis for the exploitation of diagnostic and therapeutic strategies for overcoming recurrence and metastasis in OS. 31205570 2019
CUI: C0029463
Disease: Osteosarcoma
Osteosarcoma 		0.010 Biomarker disease BEFREE Accordingly, PQBP1 and PCK2 are crucial for recurrence and metastasis in OS, and these findings provide a molecular basis for the exploitation of diagnostic and therapeutic strategies for overcoming recurrence and metastasis in OS. 31205570 2019
CUI: C0585442
Disease: Osteosarcoma of bone
Osteosarcoma of bone 		0.010 Biomarker disease BEFREE Accordingly, PQBP1 and PCK2 are crucial for recurrence and metastasis in OS, and these findings provide a molecular basis for the exploitation of diagnostic and therapeutic strategies for overcoming recurrence and metastasis in OS. 31205570 2019
CUI: C1332986
Disease: Childhood Osteosarcoma
Childhood Osteosarcoma 		0.010 Biomarker disease BEFREE Accordingly, PQBP1 and PCK2 are crucial for recurrence and metastasis in OS, and these findings provide a molecular basis for the exploitation of diagnostic and therapeutic strategies for overcoming recurrence and metastasis in OS. 31205570 2019
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.080 Biomarker disease BEFREE In a conclusion, CA can regulate glucose and lipid metabolic adaptation in T2D like HepG2, zebrafish and rat models partly through reducing inflammation and oxidative stress and suppressing PEPCK. 30867526 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.040 AlteredExpression disease BEFREE SR9009 treatment significantly decreased the mRNA level of Pck1 in mouse hepatoma Hepa-1c1c7 cells, whereas other major enzymes involved in gluconeogenesis (pyruvate carboxylase, glucose-6-phosphatase, fructose bisphosphatase and Pck2) and in glycolysis (phosphofructokinase and hexokinase-1) were unaffected. 30639375 2019
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms 		0.030 AlteredExpression group BEFREE SR9009 treatment significantly decreased the mRNA level of Pck1 in mouse hepatoma Hepa-1c1c7 cells, whereas other major enzymes involved in gluconeogenesis (pyruvate carboxylase, glucose-6-phosphatase, fructose bisphosphatase and Pck2) and in glycolysis (phosphofructokinase and hexokinase-1) were unaffected. 30639375 2019
CUI: C0028754
Disease: Obesity
Obesity 		0.010 GeneticVariation disease BEFREE Eight of the methylation sites were in genes previously associated with obesity risk (eg, PCK2, CxCl10, BCAT1, HID1, PRDM16, MADD, PXDN, GALE), with several of the findings from the discovery data set replicated in the second cohort. 30177354 2018
CUI: C0021704
Disease: Intelligence
Intelligence 		0.100 GeneticVariation phenotype GWASCAT Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. 29844566 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.020 Biomarker group BEFREE Furthermore, PEPCK-M silencing abrogated cancer growth in a lung cancer cell xenograft model. 29844165 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.020 Biomarker group BEFREE Furthermore, PEPCK-M silencing abrogated cancer growth in a lung cancer cell xenograft model. 29844165 2018
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.010 Biomarker disease BEFREE Furthermore, PEPCK-M silencing abrogated cancer growth in a lung cancer cell xenograft model. 29844165 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.010 Biomarker disease BEFREE Furthermore, PEPCK-M silencing abrogated cancer growth in a lung cancer cell xenograft model. 29844165 2018
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.010 Biomarker disease BEFREE Furthermore, PEPCK-M silencing abrogated cancer growth in a lung cancer cell xenograft model. 29844165 2018
CUI: C0022660
Disease: Kidney Failure, Acute
Kidney Failure, Acute 		0.010 Biomarker disease BEFREE Here we tested the hypothesis that renal proximal tubular PAD4 rather than myeloid-cell lineage PAD4 plays a critical role in exacerbating ischemic AKI by utilizing mice lacking PAD4 in renal proximal tubules (PAD4<sup>ff</sup> PEPCK Cre mice) or in granulocytes (PAD4<sup>ff</sup> LysM Cre mice). 29357426 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.040 AlteredExpression disease BEFREE Here, we report that the expressions of both PCK1 and PCK2 genes are downregulated in primary hepatocellular carcinoma (HCC) and low PCK expression was associated with poor prognosis in patients with HCC. 29335519 2018
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.020 AlteredExpression phenotype BEFREE Forced expression of either PCK1 or PCK2 in liver cancer cell lines results in severe apoptosis under the condition of glucose deprivation and suppressed liver tumorigenesis in mice. 29335519 2018
CUI: C0220630
Disease: Adult Liver Carcinoma
Adult Liver Carcinoma 		0.010 AlteredExpression disease BEFREE Forced expression of either PCK1 or PCK2 in liver cancer cell lines results in severe apoptosis under the condition of glucose deprivation and suppressed liver tumorigenesis in mice. 29335519 2018
CUI: C0279000
Disease: Liver and Intrahepatic Biliary Tract Carcinoma
Liver and Intrahepatic Biliary Tract Carcinoma 		0.010 AlteredExpression disease BEFREE Forced expression of either PCK1 or PCK2 in liver cancer cell lines results in severe apoptosis under the condition of glucose deprivation and suppressed liver tumorigenesis in mice. 29335519 2018
CUI: C0345904
Disease: Malignant neoplasm of liver
Malignant neoplasm of liver 		0.010 AlteredExpression disease BEFREE Forced expression of either PCK1 or PCK2 in liver cancer cell lines results in severe apoptosis under the condition of glucose deprivation and suppressed liver tumorigenesis in mice. 29335519 2018
CUI: C0042769
Disease: Virus Diseases
Virus Diseases 		0.010 Biomarker group BEFREE In contrast, transcription factor RelB (RELB), histone acetyltransferase p300 (EP300), acetyl-CoA carboxylase 2 (ACACB), adiponectin (ADIPOQ) and phosphoenolpyruvate carboxykinase 2 mitochondrial (PCK2) had major contributions to viral infections and lipid metabolism as significant events in RP. 29194580 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.030 AlteredExpression group BEFREE Information from prostate cancer patient databases revealed that higher PCK2 levels correlated with more aggressive tumors and lower survival rates. 29137367 2017
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.010 Biomarker group BEFREE Thus, PCK2 is a potential therapeutic target for aggressive prostate tumors. 29137367 2017